Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

USANA

This article was originally published in The Tan Sheet

Executive Summary

Projected fourth quarter net sales of more than $37 mil. would be firm's highest quarterly revenues ever, Salt Lake City-based supplement direct seller says Dec. 18. Stronger-than-expected results were driven by "an increased number of associate enrollments, spurred by the newly launched Taiwan market and continued growth in each of our major markets," USANA states. Firm announced plan to enter Taiwan earlier this year (1"The Tan Sheet" May 13, 2002, In Brief)...

You may also be interested in...



USANA expansion

Direct marketer's entry into Taiwan slated for Q4. Company putting infrastructure in place and obtaining product approvals, also plans to leverage existing resources in Hong Kong, Australia to support Taiwan entry. One-time costs associated with suspended effort to take direct marketer private result in Q1 earnings per share impact of 3¢, USANA says April 25. Nevertheless, net earnings rose 140% from year-ago quarter to $1.1 mil. on a 3.7% sales gain to $28.6 mil. Improved margins resulted from production efficiencies, adjustment in pricing strategy, firm explains. USANA founder Myron Wentz cited company's improved performance as reason for terminating his bid to take it private (1"The Tan Sheet" April 15, 2002, p. 5)...

Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round

Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.

Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children

Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094951

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel